Select Medical beats Q3 revenue estimates

Select Medical Holdings

30/10/2025 20:44

Overview

Select Medical Q3 revenue grows 7.2%, beating analyst expectations

Adjusted EPS for Q3 declines compared to prior year

Company extends stock repurchase program to December 2027

Outlook

Select Medical expects 2025 revenue between $5.3 bln and $5.5 bln

Company reaffirms 2025 Adjusted EBITDA between $510 mln and $530 mln

Select Medical raises 2025 EPS outlook to $1.14-$1.24

Result Drivers

REHABILITATION HOSPITAL GROWTH - Revenue for the rehabilitation hospital segment increased 16.2%, contributing significantly to overall revenue growth

CRITICAL ILLNESS RECOVERY - Revenue for the critical illness recovery hospital segment increased 4.6%, indicating modest growth

COST MANAGEMENT - General and administrative expenses decreased by 15.4%, aiding profitability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$1.36 bln
$1.33 bln (6 Analysts)
Q3 Adjusted EBITDA
$111.70 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Select Medical Holdings Corp is $19.00, about 24.8% above its October 29 closing price of $14.28

Press Release: ID:nPn34107Qa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)